Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 2/20 | 0.39 |
| ▸ | GMNN | O75496 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 2/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.39 |
| ▸ | APEX1 | P27695 | 2/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.39 |
| ▸ | RECQL | P46063 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | EP300 | Q09472 | 1/20 | 0.38 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.37 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1555372 | 0.94 | TSHR (0.41) | CNR1GMNNUSP2CYP1A2POLB | |
| SCHEMBL1556242 | 0.85 | CYP3A4 (0.33) | CYP1A2POLBCYP2C9CYP2C19CYP3A4 | |
| SCHEMBL420349 | 0.82 | EPHX1 (0.52) | CYP1A2BLMHSD17B10MAPT | |
| SCHEMBL1556988 | 0.78 | L3MBTL1 (0.36) | CYP1A2POLBRECQLASAH1CNR2 | |
| SCHEMBL1556426 | 0.77 | EP300 (0.42) | GMNNUSP2CYP1A2POLBCYP2C9 | |
| SCHEMBL7708913 | 0.76 | EPHX1 (0.48) | CYP1A2POLBBLMHSD17B10MAPT | |
| SCHEMBL10744068 | 0.76 | CTSK (0.40) | CNR1CNR2 | |
| SCHEMBL9800734 | 0.75 | EP300 (0.50) | GMNNUSP2CYP1A2POLBCYP2C9 | |
| SCHEMBL1415923 | 0.75 | FAAH (0.48) | CNR1GMNNUSP2CYP1A2POLB | |
| SCHEMBL1556892 | 0.75 | PPARG (0.42) | CNR1EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120301552-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2012-11-29 | — | — | US | disclosed |
| EP-2308828-A2 | CaSR antagonist | Japan Tobacco Inc. (JP) | 2011-04-13 | — | — | EP | disclosed |
| EP-2189439-A2 | CaSR antagonist | Japan Tobacco, Inc. (JP) | 2010-05-26 | — | — | EP | disclosed |
| US-20090326058-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-1619180-B1 | CaSR ANTAGONIST | JAPAN TOBACCO INC (JP) | 2009-12-16 | — | — | EP | disclosed |
| US-20080255042-A1 | CaSR Antagonist | JAPAN TOBACCO INC. (JP) | 2008-10-16 | — | — | US | disclosed |
| US-7304174-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-12-04 | — | — | US | disclosed |
| US-7285572-B2 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2007-10-23 | — | — | US | disclosed |
| US-20060135572-A1 | CaSR antagonist | JAPAN TOBACCO INC. (JP) | 2006-06-22 | — | — | US | disclosed |
| EP-1630157-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-03-01 | — | — | EP | disclosed |
| EP-1619180-A1 | CaSR ANTAGONIST | JAPAN TOBACCO INC. (JP) | 2006-01-25 | — | — | EP | disclosed |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | JAPAN TOBACCO INC. | 2005-02-10 | — | — | US | disclosed |
| EP-0267024-B1 | HYDROFLUORENE DERIVATIVES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326058-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CNR1 79/4885GMNN 4792/4885USP2 3867/4885 |
| US-20060135572-A1 | CaSR antagonist | CASR, CALCR, CALCRL | CNR1 55/4885GMNN 4829/4885USP2 3979/4885 |
| US-20120301552-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CNR1 79/4885GMNN 4792/4885USP2 3867/4885 |
| US-20080255042-A1 | CaSR Antagonist | CASR, CALCR, CALCRL | CNR1 79/4885GMNN 4792/4885USP2 3867/4885 |
| US-20050032796-A1 | Compounds as for example, 2'-[1-[(2R)-3-[[1-(3-fluoro-4-methylphenyl)-2-methylpropan-2-yl]amino]-2-hydroxypropoxy]ethyl]-3-methylbiphenyl-4-carboxylic acid, having a calcium-sensing receptor antagonistic action; therapeutic drug for osteoporosis | CASR, CALCR, GRK2 | CNR1 291/4885GMNN 4307/4885USP2 4413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.